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Biofilm accounts for 65%-80% of microbial infections in humans. Considerable evidence
links biofilm formation to oral disease and consequently systemic infections. Eradication of biofilmassociated infections is important. Streptococcus sanguinis, a Gram-positive bacterium, is one of the
most abundant species in oral biofilm. It contributes to biofilm development in oral cavities and is
one of the recognized causes of infective endocarditis. To study and identify biofilm genes in S.
sanguinis, biofilm formation of 51 mutants was compared with the wild type SK36 strain using
crystal violet (CV) staining in a microtiter plate. Confocal laser scanning microscopy (CLSM) and
image analysis was done to compare biofilm formation by the mutant to the wild type SK36 strain. A
biofilm mutant XG2_0351, encoding a type I signal peptidase (SPase I), was further investigated.
SPase I cleaves proteins that are transported through secretory machinery and is necessary for the
release

of

translocated

preproteins

from

a

cytoplasmic

site

of

synthesis

to

extracytoplasmic/membrane destinations. S. sanguinis, like many Gram-positive bacteria, has
multiple SPases I. The objective of this project is to investigate the distinctive role that SPase I plays
in biofilm formation in S. sanguinis. Using a plate reader, the growth curves of the wild type strain
SK36 and XG2_0351 were compared. The scanning electron microscope (SEM) was utilized to
compare the cell surface morphologies. Coomassie staining was done to narrow the list of potential
substrates of XG2_0351. CV staining and CLSM images indicated phenotypic differences between
the SPase I mutant and SK36. The growth curves of XG2_0351 and SK36 showed no significant
difference although SEM illustrated a difference in the cell surface morphologies. Coomassie
staining illustrated a number of substrates that were present in SK36 but not XG2_0351. In addition
bioinformatics was used to understand the gene function. In conclusion, XG2_0351 reduces biofilm
formation in S. sanguinis but further research is necessary to elucidate the specific proteins that are
involved. Clarifying the
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role that SPase I plays in reduced biofilm formation in S. sanguinis will give a better
understanding of the biofilm formation mechanism.
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INTRODUCTION
The highly developed oral microbiome is a diverse environment that is largely influenced by
oral streptococci (Kreth, Merritt, & Qi, 2009). Streptococcus sanguinis, a gram-positive
bacterium, is a known pioneer colonizer on freshly cleaned tooth surfaces and one of the
abundant species in oral biofilm (Ge et al., 2008; Jenkinson & Lamont, 2005). As most members
of the viridans group, S. sanguinis oxidizes hemoglobin in erythrocytes by secretion of H2O2 and
produces alpha-hemolysis on blood agar (Barnard & Stinson, 1996; Xu et al., 2007). Through a
variety of mechanisms, normal inhabitant streptococci form dental plaque which is involved in
the development of caries. To initially colonize the tooth surface and form dental plaque,
streptococci serve as a tether for the attachment of other microorganisms to a salivary
glycoprotein-coated surface (Kolenbrander & London, 1993; Xu et al., 2007). One of these
microorganisms is S. mutans, whose overgrowth is often associated with the development of
dental caries (Kreth, Merritt, Shi, & Qi, 2005; Loesche, 1986). The shift from a healthy to
cariogenic streptococcal environment is caused by coexistence and competition of interspecies
interactions in a microbial community. Steering the outcome of interactions between species are
determining environment conditions, such as nutritional availability, cell density, and pH (Kreth
et al., 2005). Significantly higher number of S. sanguinis is reported in healthy subjects whereas
there is almost no detectable level in those subjects with caries. An inverse relationship between
commensal and pathogenic streptococci exists where a high levels S. sanguinis correlated with
subsequent delayed acquisition of S. mutans (Caufield et al., 2000; Kreth et al., 2005). Through a
well-regulated production of chemicals, such as H2O2 by S. sanguinis and mutacins by S. mutans
these interspecies interactions are mediated (Kreth et al., 2005). Thus we can presume that the
ability of S. sanguinis to interfere with the colonization of S. mutans on a tooth may be
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beneficial for oral health (Caufield et al., 2000; Xu et al., 2007). Although S. sanguinis is a
member of the normal flora in the oral cavity and is considered benign, it has the potential to be
pathogenic in patients through bacteremia (Ge et al., 2008; Turner, Das, Kanamoto, Munro, &
Kitten, 2009; Xu et al., 2007). This opportunistic pathogen infection could lead to infective
endocarditis or cause fatality in patients who are neutropenic (Bochud, Calandra, & Francioli,
1994; Ge et al., 2008; Xu et al., 2007).

Biofilm
Biofilm is an accumulation of microorganisms embedded in a protective extracellular
polymeric matrix that adheres to biotic or abiotic surfaces in nature (Hall, McGillicuddy, &
Kaplan, 2014). This accumulation of either a single or multiple species lives in a nutrientsufficient ecosystem as a sessile microbial community. Biofilm exhibits a distinct
physiologically altered pattern when compared to the gene expression and protein production of
planktonic cells (Costerton, Stewart, & Greenberg, 1999; Donlan, 2002; Hall et al., 2014).
Furthermore, an extracellular polymeric substance (EPS) matrix is produced to differentiate the
biofilm-associated cells from the suspended planktonic cells (Donlan, 2000). The composition
and structure of the polysaccharides in the EPS matrix determine their primary conformation.
Usually the EPS in not uniform but varies spatially and temporally (Donlan & Costerton, 2002;
Leriche, Sibille, & Carpentier, 2000). It is possible that the high level of hydration of the EPS
prevents desiccation in some natural biofilms. The EPS can also impede the mass transport of
antibiotics through the biofilm, which may promote their antimicrobial resistance properties
(Donlan, 2000; Donlan, 2002). The formation of biofilm occurs in five major stages: initial
attachment, irreversible attachment, maturation I, maturation II and dispersal.
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Microbial surface components mediate attachment through surface proteins by recognizing
adhesive matrix molecules (MSCRAMMs) (Foster, Geoghegan, Ganesh, & Hook, 2014; Lister
& Horswill, 2014). Initially, bacteria adhered to the surface begin to multiply and differentiate,
strengthening the attachment (Lister & Horswill, 2014). The maturation process occurs through
the up-regulation of virulence factors, secretion of extra-cellular polymers, consumption of
soluble nutrients, and recruitment of other bacterial species (Hall et al., 2014). When a biofilm is
fully established it has a defined structure where the environment is conducive for the exchange
of genetic material between cells (Donlan, 2002). Biofilm growth is an important advantage for
bacteria because it provides a defense system against immune defenses such as macrophages.
This can result in “frustrated phagocytosis” (Lister & Horswill, 2014; Scherr, Heim, Morrison, &
Kielian, 2014). Biofilms demonstrate quorum sensing, which is cell-to-cell signaling that plays a
role in cell attachment and detachment (Donlan, 2000). The cells of a biofilm may disperse by
detachment caused by nutrient levels or quorum sensing, shearing of biofilm aggregates because
of flow effects, or shedding of daughter cells from actively growing cells (Donlan, 2002).
Eventually, individual cells from the original biofilm can disperse to start infection at new sights
or mediate an acute infection (Costerton et al., 1999; Lister & Horswill, 2014).
According to estimates by the U.S. Centers for Disease Control and Prevention and the
National Institutes of Health, biofilm accounts for 65%-80% of microbial infections in human
beings (Donlan, 2002; Hall et al., 2014). Infections that are biofilm-based have been discovered
in almost all tissues of the human body (Hall et al., 2014). Many studies have shown that there is
considerable evidence linking biofilm formation in the oral cavity to oral disease and
consequently systemic infections. These systemic conditions include cardiovascular disease,
diabetes mellitus, preterm or low birth weights, rheumatoid arthritis, and infective endocarditis
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(Hall et al., 2014; Seymour, Ford, Cullinan, Leishman, & Yamazaki, 2007). Biofilm growth has
the ability to use a variety of defense mechanisms against infection so treatment and eradication
of biofilm-associated infections are problematic and difficult (Hall et al., 2014). Cells in a
biofilm show increased tolerance to antibiotics through different mechanisms. The biofilm
matrix blocks access to actively growing cells by decreasing the antibiotic diffusion rates or
physiologically dormant persister cells which are inherently resistant to antibiotics (de la FuenteNunez, Reffuveille, Fernandez, & Hancock, 2013; Lister & Horswill, 2014; Singh, Ray, Das, &
Sharma, 2009)

Infective Endocarditis
Infective endocarditis (IE) is a potentially life-threatening microbial infection of the heart
valves or endocardium (Cahill & Prendergast, 2015; Hoen & Duval, 2013; Selton-Suty et al.,
2012). This disease has an estimated annual incidence of 3 to 9 cases per 100,000 people in
industrialized countries (Hoen & Duval, 2013; Selton-Suty et al., 2012). In 2016, there are many
emerging treatments and therapies for endocarditis but the 1-year mortality rate remains at 30%
(Cahill & Prendergast, 2015). If not treated, IE can result in severe complications such as
congestive heart failure and can become fatal.
Patients with prosthetic valves, intracardiac devices, unrepaired cyanotic congenital heart
diseases, or a family history of IE have the highest rates of this illness. However, 50% of
incidences of IE develop in patients with no known history of valve disease. There are several
other risk factors for IE such as chronic rheumatic heart disease, hemodialysis, diabetes, HIV,
and intravenous drug use (Hoen & Duval, 2013). In the United States, more than one third of the
cases of IE are reported to be health care-associated. When several predisposing factors are
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associated with age, the increased number of cases of IE among persons 65 years of age or older
is clear (Hoen & Duval, 2013; Selton-Suty et al., 2012).
Together, streptococci and staphylococci account for 80% of cases of IE. The proportions
vary with regards to the source of infection, patient age, coexisting conditions, and valve (native
vs. prosthetic) (Hoen & Duval, 2013). Recent studies have shown that staphylococci, specifically
S. aureus, have surpassed streptococci as the most common cause of IE. IE by the streptococcal
oral viridians group remain the most common in low-income countries (Cahill & Prendergast,
2016; Yew & Murdoch, 2012). Although S. sanguinis has no direct role in oral disease, it is often
implicated as the most common streptococci isolated from patients (Mylonakis & Calderwood,
2001).

Pathogenesis of Infective Endocarditis
Conventional IE results when there is colonization of damaged valvular endothelium by
circulating bacteria with specific adherence properties. Lesions that cause endothelial damage
may be the result of turbulent blood, catheters, electrodes, or by repeated intravenous-drug use
(Hoen & Duval, 2013). Certain types of congenital or acquired heart disease cause turbulent
blood flow, traumatizing the endothelium and causing the deposition of fibrin and platelets on
the damaged endocardium or endothelial surface. IE results when microbes invade the
bloodstream and colonize this damaged site. Microbial organisms cause IE when they
disseminate into the bloodstream and the intricately composed biofilm within the gingival tissue
niche is disrupted. A disturbance of the delicate barrier between the oral biofilm and host tissues
may cause periodontitis, gingivitis, pulpal or root canal infections. There is a heightened risk of
bacteremia when an increase of inflammation results from oral procedures and even routine oral
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procedures such as brushing, flossing, and chewing (Parahitiyawa, Jin, Leung, Yam, &
Samaranayake, 2009).
IE clinical manifestations can vary dramatically depending on the specific case. In 80% of
cases fever is a prevalent symptom (Hoen & Duval, 2013; Selton-Suty et al., 2012). Also, a new
murmur and worsening of a known murmur are reported. Less common signs are splenomegaly,
splinter hemorrhages, Janeway’s lesions, Roth’s spots, conjunctival hemorrhage, sepsis,
meningitis, unexplained heart failure, septic pulmonary emboli, stroke, acute peripheral arterial
occlusion, and renal failure (Hoen & Duval, 2013; Richet et al., 2008). The most severe
extracardiac problems of infective endocarditis are cerebral complications (Hoen & Duval, 2013;
Sonneville et al., 2011; Thuny et al., 2007).
Diagnostic methods for IE generally rely on clinical, microbiologic, and echocardiographic
findings. To identify the causative microorganism, three sets of blood cultures are performed and
the pathogen is identified in 90% of cases. Transthoracic echocardiography is performed to
diagnose valvular lesions (Hoen & Duval, 2013). The polymerase chain reaction can be utilized
to identify unculturable organisms in excised vegetations or systemic emboli (Beynon, Bahl, &
Prendergast, 2006; Mylonakis & Calderwood, 2001). Appropriate treatment for patients with IE
revolves around prolonged bactericidal antibiotic treatment to eradicate the causative pathogen
and possible surgery to remove the infected material (Hoen & Duval, 2013).
If there is no need for cardiac surgery, effective treatment for IE using antimicrobial agents
begins in the hospital. Often this treatment is completed on an outpatient basis once the fever has
resolved and follow-up blood cultures are negative. For common causes of IE, prolonged
administration of a bactericidal antimicrobial agent or combination is currently recommended
(Mylonakis & Calderwood, 2001). Granted, it is advised to use combination therapy over
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monotherapy to reduce the potential for resistance development and to provide a concerted
antimicrobial effect (Cahill & Prendergast, 2016). There is a high frequency of adverse events in
patients who are being treated for IE so therapy revision is important (Mylonakis & Calderwood,
2001). The antimicrobial regimen can be modified depending on resistance patterns, severity of
infection, presence or absence of prosthetic material, and culture results (Cahill & Prendergast,
2016). The minimal inhibitory concentration (MIC) of penicillin is necessary to determine the
optimal therapy for streptococcal infection. Antibiotic therapy for IE caused by some
microorganisms is frequently unsuccessful, and surgery is generally recommended (Mylonakis &
Calderwood, 2001).
IE presents many challenges because it is heterogeneous and complex by nature. Even though
there have been many advances in diagnostic procedures, antimicrobial treatments, and
cardiovascular imaging it remains a serious threat to many lives (Cahill & Prendergast, 2015). As
of 2015, IE has an incidence of 3 to 10 per 100,000 and has an in-hospitality of 20% (Cahill &
Prendergast, 2015; Cahill & Prendergast, 2016). Therefore, it is imperative to study the causative
agents and virulence factors of IE.

Importance of Signal Peptidase I
Almost one-third of all proteins need to be translocated through or into the cytoplasmic
membrane because they function outside of the cytosol (Auclair, Bhanu, & Kendall, 2012).
These preproteins are directed to the Sec- or Tat-translocation pathway by the signal sequence,
an amino-terminal extension. In prokaryotes, signal peptidases (SPases) are classified into three
groups: SPase I, II, and IV. SPase II and IV are necessary for cleaving signal peptides from
lipoproteins and prepilin proteins, respectively. SPase I produces mature non-lipoproteins that
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are then transported in bacteria by the general secretion (Sec) pathway. However there is recent
evidence that indicates that SPase I can also be transported by means of the twin arginine
translocation (Tat) pathway (Auclair et al., 2012; Luke, Handford, Palmer, & Sargent, 2009).
SPase I is essential to the cell for the release of translocated preproteins from the membrane
when they are transported from a site of cytoplasmic synthesis to extracytoplasmic locations
(Auclair et al., 2012; du Plessis, Nouwen, & Driessen, 2011). The protein extracytoplasmic
location and specific secretion pathway destination are determined by the signal peptide which
marks the protein with a zipcode. The signal peptidase enzyme has the responsibility of cleaving
the signal peptide from the preprotein once the majority of it is translocated. This enzymatic
action allows the protein to release from the membrane and correctly fold into a mature protein.
SPase enzymes are critical for cell survival because without them, accumulation of preproteins at
the membrane would occur and have a deleterious effect on the growth of the cell (Dalbey &
Wickner, 1985; Auclair et al., 2012). Bacterial species such as E. coli have only one essential
SPase I enzyme whiles others such as B. subtilis have multiple enzymes (Auclair et al., 2012;
Meijer et al., 1995; Tjalsma et al., 1997; Tjalsma et al., 1998). S. sanguinis possesses two SPase I
enzymes: XG2_0351 AND XG2_0849. The bacterial SPase I belongs to a unique group of serine
endoproteases, which use a Ser-Lys catalytic dyad instead of the standard Ser-His-Asp triad
utilized by eukaryotes. This distinctive feature makes SPase I a desirable antimicrobial target
(Rawlings & Barrett, 1993; Auclair et al., 2012).
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Purpose of Study
Identifying which genes in S. sanguinis can cause biofilm formation and their mechanisms is
an important step in being able to effectively prevent and treat systemic infections that originate
in the oral cavity. In this study we attempted to elucidate the role that SPases I plays in biofilm
formation in S. sanguinis when a paralogue is available. In the future, S. sanguinis will be used
as a model for further study of biofilm genes in other types of bacteria.
Genome-wide deletion mutants of S. sangunis strain SK36 have been constructed in our
laboratory. The comprehensive library of deletion mutants of SK36 provided the unique
opportunity to apply a systems biology approach to investigate the effect of genetic mutations on
biofilm formation.
This study involved the observation of phenotypic characteristics of biofilm formation by the
non-essential deletion mutants and the wild type of S. sanguinis SK36 using crystal violet
staining and confocal laser scanning microscopy. Cell morphologies for selected mutant
XG2_0351 and SK36 were compared through visualization by scanning electron microscopy. To
compare the growth between SK36 and XG2_0351 the growth curves were examined using a
plate reader. Computational prediction data was used to gain more knowledge about gene
interactions and functional similarities to other species. Finally, coomassie staining was done to
narrow the list of potential substrates of XG2_0351 involved in biofilm formation.
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METHODS AND MATERIALS
Bacterial strain and mutants
S. sanguinis strain SK36 that was used in this study (Table 1) was isolated from human
dental plaque (Kilian, Mikkelsen, & Henrichsen, 1989). Single gene deletion mutants for the
SK36 strain were previously constructed using a recombinant PCR method (Figure 1). Utilizing
the complete S. sanguinis SK36 genome sequence, three sets of primers (F1/R1, F2/R2, and
F3/R3) were designed. Primers were constructed to amplify a linear DNA fragment containing a
kanamycin resistance cassette flanked by upstream and downstream sequences of the targeted
gene. The 5’ ends of the F2 and R2 of primers of the kanamycin cassette were created to
complement the sequences of DNA that flank the target gene (Xu et al., 2011). The linear
recombinant PCR amplicons containing the kanamycin cassette (Turner, Das, Kanamoto, Munro,
& Kitten, 2009) flanked by S. sanguinis DNA were transformed into competent S. sanguinis
cells and integrated into the S. sanguinis genome via double crossover recombination (Ge et al.,
2008). A genome-wide mutant library containing 2,048 deletion mutants was constructed using a
96 well high-throughput format (Chen et al., 2011; Xu et al., 2007). To determine putative gene
functions proteins were searched against the previously annotated genome (Ge et al., 2008; Xu et
al., 2007). Genes of SK36 are referred to as “SSA” followed by the corresponding gene number
while mutants are indicated by “XG2” followed by the gene number.
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Table 1. Bacterial strains used in study.
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Table 1.

Strain

Phenotype

Source

S. sanguinis
SK36

Human dental plaque isolate

[Kilian 1989, Xu 2007]

SK36 mutants

All non-essential gene deletion mutants
of SK36 from genome-wide library

[Xu 2007, Chen 2011]
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Figure 1. Schematic representation of the insertion of kanamycin (Km) resistance gene cassette
into SK36 chromosome to construct single gene deletion mutants.
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Figure 1.
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Crystal Violet Assay
To study and identify biofilm genes in S. sanguinis, 51 mutants were compared with the wild
type SK36 strain using the microtiter dish biofilm formation assay. Using preliminary data from
our lab (Table 2), the set of 51 mutants were tested for biofilm formation using the O’Toole
method to observe bacterial adherence to an abiotic surface (O'Toole, 2011). This method was
also used to test the downstream gene of XG2_0351, as well as its paralogue: XG2_0849. SK36
and mutants were grown anaerobically in BHI and BHI supplemented with kanamycin
respectively, and incubated at 37°C for 16 hours. A multichannel pipette was used to inoculate a
96-well plate with 99 µl of biofilm medium supplemented with 1% sucrose and 1 µl of overnight
culture of SK36 of each mutant for 8 repeats. One column of 8 wells was loaded with medium
alone as a negative control. The total bacterial growth was determined by measuring the
absorbance at 450 nm with a Synergy H1 Hybrid Reactor (BioTek, VT, USA) microplate reader.
We decanted the media and then removed the remaining planktonic cells by gently rinsing with
200 µl of distilled H2O. 50 µl of 0.4% (wt/vol) crystal violet (CV) solution was added to each
well and was left for 15 minutes to dry. Wells were rinsed three times with 200 µl of distilled
H2O and air-dried. The CV was solubilized by 200 µl of 33% acetic acid. After 30 minutes, 100
µl from each well was transferred to a new plate and the absorbance at 600 nm was measured by
a Synergy H1 Hybrid Reactor (BioTek, VT, USA) microplate reader. The results from microtiter
staining were statistically analyzed by ANOVA. The significance was set as P-value <0.05 (Ge
et al., 2008).
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Confocal Laser Scanning Microscopy (CLSM) and Image Analysis
Confocal laser scanning microscopy and image analysis was used to further study and identify
biofilm genes in S. sanguinis. Six wells in a 12 well-plate were filled with 1000 µl of biofilm
medium supplemented with 1% sucrose and inoculated with 10 µl of overnight culture. The first
column contained SK36 and the second contained a mutant for 3 repeats each. Overnight
biofilms were rinsed 1 time with 1000 µl of PBS to remove the unattached bacteria. For 15
minutes, biofilms were labeled using live staining. This was done with 1.5 µM SYTO9 (a green
fluorescent dye that can cross intact membranes). Afterwards the wells were rinsed with 1000 µl
of PBS to remove the remaining dye. The biofilms were viewed through a 10x dry lens with a
Zeiss LSM 710 confocal laser scanning microscope. Green fluorescence was imaged and an
image stack of 1 randomly chosen spot was collected for each sample. The computer program
ImageJ analyzed CLSM images. Image stacks were converted to individual Tiff images for the
front, middle, and side of each sample. The image stacks of biofilm grown by the mutant were
compared to growth by the wild type by using the T-test. This method was also used to test the
downstream gene of XG2_0351, as well as its paralogue: XG2_0849.
Confocal Laser Scanning Microscopy and Scanning Electronic Microscopy were performed
at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported in part,
by funding from NIH-NCI Cancer Center Support Grant P30 CA016059.
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Examination of Mutant Growth in vitro
This experiment was done to elucidate and compare growth rates of SK36 and XG2_0351.
The wild type and mutant were inoculated individually and then measured for three trials
concurrently using a Synergy H1 Hybrid Reactor (BioTek, VT, USA) microplate reader for 1416 hours.

Elucidated Gene Functions using Clusters of Orthologous Groups
Using PubMed (http://www.ncbi.nlm.nih.gov/pubmed), we searched for mutant genes that
are organized into operons (Table 3). Uniprot (http://www.uniprot.org/) was utilized to search
clusters of orthologous groups (COGs) (Table 3).

STRING Analysis and Gene Co-occurrence Network
The STRING database (http://string-db.org/) provided a way to visualize and predict proteinprotein interactions of XG2_0351 through bioinformatics data (Figure 7A). The co-occurrence
network shows the relationship between XG2_0351 with other bacterial species (Figure 7B).

Scanning Electron Microscopy (SEM) Analysis of S. sanguinis WT and Mutant Cells
The cell morphologies of S. sanguinis SK36 and selected mutant XG2_0351 were examined
using SEM (Figure 5). The two samples were deposited onto a 0.1 μm disposable Millipore filter
to remove medium. Samples were fixed using 2% glutaraldehyde in 0.1 M sodium cacodylate
buffer (pH 7.4) for 30 min, followed by 1% osmium tetroxide in 0.1 M sodium cacodylate buffer
(pH 7.4). The samples embedded in the filters were then dehydrated in ethanol followed by
phosphate-buffered saline (PBS) and allowed to air-dry. The filters were sectioned and mounted
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onto stubs and coated with gold for three minutes (EMS– 550 Automated Sputter Coater,
Electron Microscopy Sciences, Hatfield, PA). Micrographs were taken at 15,000× total
magnification using a Zeiss EVO 50 XVP scanning electron microscope (Carl Zeiss, Peabody,
MA).

Coomassie Staining
This staining assay was done to elucidate which proteins XG2_0351 is targeting (Figure 11).
We inoculated the stocked strain into 5 ml medium (e.g. BHI) in a 15 ml round-bottom tube.
After this we prepared 3 round-bottom tubes of 15 ml containing 5 ml medium, and then
incubated them in an anaerobic jar at 37 °C for overnight. Then we transferred 50 μl overnight
bacterial culture into each of 3 pre-incubated conical tubes and incubated at the same condition
as previously stated to mid log-phase (about 4 hours). All of the following steps were done at 4
°C. Bacterial cells were centrifuged for 10 min at 4,000 rpm using Sorvall Legend RT centrifuge
(MN, USA). Following this we added 10 μl protease inhibitor cocktail (Sigma P8430) and
DNase (1 μg/ml) to 1 ml non-denaturing lysis buffer (PBS, EDTA=5 mM, pH = 7.4) to 106 cells
in mid log-phase bacterial culture. We re-suspended the pellets by pipetting up and down several
times. The suspension was transferred into the 2 ml Lysing Matrix B Beads. Cells were disrupted
in the Fast Prep 24 for 30s at level 4. Then we sonicated for short pulses (5-10 sec) with pauses
(10-30 sec) to re-establish a low temperature. We centrifuged for 10s at maximum speed and
transferred supernatant into a new tube. Then we determined the volume of the supernatant and
quantitated the protein in sample using Pierce BCA Protein Assay kit (Cat #23227, IL, USA). 15
µg of protein were loaded into each well and stained with Coomassie
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Brilliant Blue R-250 solution (Bio-Rad, USA) for 4 hours. Finally, we washed with washing
buffer (50 % methanol, 10% acetic acid, 40% distilled water) until bands were visible.
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RESULTS
We compared 51 mutants to SK36 using crystal violet staining to determine if there is a
statistically significant difference in biofilm formation (Figure 2). Using the ANOVA statistical
test, we determined t-test with p-values <0.05 were statistically different. We found that 41
mutants formed biofilms that were statistically significant when compared to SK36. Using a
multiple comparison method known as Dunnett's test, we found that XG2_0351 has a p value
<.0001 when compared to SK36. 25 mutants that showed less biofilm formation than SK36 were
viewed via CLSM. Using CLSM, z-stacks were created by stacking successive slices, which
were then processed into a 3D image using ImageJ software (Figure 3). The z-stack for
XG2_0351 showed effectively no biofilm formation and therefore, was much thinner than SK36.
The downstream mutant, XG2_0350 was tested to rule out the possibility of the polar effect
(Figure 8). XG2_0351 was selected for further investigation based on phenotypic differences
with SK36 that were determined by CV staining and CLSM.
SEM was used to visualize the morphological differences between SK36 and type I
signal peptidase mutant XG2_0351 (Figure 5). Biofilm did not form during CV staining or
CLSM, XG2_0351 showed growth in SEM images. Although, the mutant chains were much
shorter in length and had a different shape than SK36. To gain more insight into the growth
differences we looked at the growth curves by using a plate reader (Figure 6). Three separate
repetitive trials showed that the growth rate of SK36 and XG2_0351 are not significantly
different.
Through computational prediction methods, the STRING database predicted that this
signal peptidase I protein interacts with signal recognition particles and several ribosomal
proteins (Figure 7A). Gene co-occurrence showed that SPase I shares many similarities with the
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Firmicutes phylum (Figure 7B). CLSM was utilized to visualize XG2_0849, the paralogue of
XG2_0351, for biofilm formation (Figure 9). The mutant showed a slight difference in biofilm
formation when compared to SK36 but lacked the dramatically decreased effect seen by
XG2_0351. Finally, the coomassie assay was done to see the concentrations of proteins that are
in SK36 but missing in XG2_0351 (Figure 11). Nine substrates of SPase I mutant, XG2_0351,
that were previously shown through CV staining and confocal imaging to exhibit reduced
biofilm formation, were absent in XG2_0351 in comparison to wild type.
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Table 2. Gene annotation of biofilm mutants
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Table 2.
Biofilm Mutant
XG2_0004
XG2_0036
XG2_0048
XG2_0115
XG2_0144
XG2_0299
XG2_0305
XG2_0351
XG2_0363
XG2_0364
XG2_0387
XG2_0460
XG2_0613
XG2_0708
XG2_0758
XG2_0767
XG2_0805
XG2_0816
XG2_0879
XG2_0960
XG2_1030
XG2_1064
XG2_1068
XG2_1103
XG2_1171
XG2_1219
XG2_1271
XG2_1301
XG2_1309
XG2_1363
XG2_1368
XG2_1371

Gene Annotation
Lipoprotein, putative
Secreted protein, possible function in cell-wall metabolism (amidase), putative (Nacetylmuramoyl-L-alanine amidase)
Transcriptional regulator, TetR/AcrR family, putative
50S ribosomal protein L29, putative
Transcriptional regulator, TetR family, putative
Integral membrane protein / nodulin 21-like protein
Heat-inducible transcription repressor/Conserved hypothetical protein/p-hydroxybenzoic acid
efflux subunit AaeB
Signal peptidase I, putative
D-alanine/glycine/Na permease, putative
Serine/threonine:Na+ symporter, putative
Transcriptional regulator, GntR family, putative
Multiple antibiotic resistance operon transcription repressor (MarR), putative
Glucosyltransferase, putative
Hypothetical protein ( isoprenylcysteine carboxyl methyltransferase (ICMT) family protein)
Ornithine acetyltransferase / amino-acid acetyltransferase, putative
Diacylglycerol kinase catalytic domain protein, putative
Collagen-binding surface protein, putative
Copper transport operon or penicillinase transcription repressor, putative
Cell division regulator, negative regulator of FtsZ septation ring formation, putative
Sensor protein ciaH, putative
Transcriptional regulator, TetR family, putative
Hypothetical protein (dextransucrase/glucansucrase, N-acetylmuramoyl-L-alanine amidase,
family 2 )
Transcriptional regulator, LysR family (capsular polysaccharide biosynthesis regulation),
putative
Hypothetical protein/ABC transporter?/capsular polysaccharide biosynthesis
protein?/PAS/PAC sensor signal transduction histidine kinase
Tyrosine recombinase xerC
Sortase, putative
DHH subfamily 1 protein/Exopolyphosphatase-related proteins
Conserved uncharacterized protein, possible surface protein
Predicted RNA-binding protein (contains KH domain), very conserved, putative
FmtA-like protein, putative
Hypothetical protein (beta-lactamase)
FmtA-like protein, putative (beta-lactamase family protein)
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XG2_1451
XG2_1476
XG2_1741
XG2_1744
XG2_1792
XG2_1845
XG2_1984
XG2_2094
XG2_2128
XG2_2138
XG2_2150
XG2_2170
XG2_2205
XG2_2234
XG2_2320
XG2_2331
XG2_2333
XG2_2335
XG2_2346
XG2_2364
XG2_2386

Exonuclease RexA, putative
Phosphoglycerol transferase and related proteins, alkaline phosphatase superfamily, putative
ABC-type Fe3+-siderophores transporter, ATPase component, putative
Iron compound ABC transporter, permease protein, putative
Preprotein translocase subunit YidC, putative
Serine/threonine protein kinase, putative
Cell surface SD repeat antigen precursor, putative
Spermidine synthase/hemolysin-type calcium-binding region
Transporter, major facilitator family protein/ transport of a lantibiotic
RNA-binding protein, Jag family, putative
Transglycosylase associated protein/Predicted membrane protein, putative
Peptidase, S54 (membrane-associated serine protease)
Transcription antitermination factor NusG, putative
Phosphatidylserine/phosphatidylglycerophosphate/cardiolipin synthases and related enzymes,
phospholipase D family, putative
Uncharacterized protein
Protein involved in D-alanine esterification of lipoteichoic acid and wall teichoic acid (Dalanine transfer protein), putative
Integral membrane protein, putative
D-Ala-teichoic acid biosynthesis protein, putative
3-oxoacyl-[acyl-carrier-protein] synthase III, putative
Immunodominant staphylococcal antigen A precursor, putative
Conserved hypothetical protein
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Table 3. Biofilm mutants with COG function, operon, and paralogue.
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Table 3.
SSA
SSA_0004
SSA_0036
SSA_0048
SSA_0115
SSA_0144
SSA_0299
SSA_0305
SSA_0351
SSA_0363
SSA_0364
SSA_0387
SSA_0460
SSA_0613
SSA_0708
SSA_0758
SSA_0767
SSA_0805
SSA_0816
SSA_0879
SSA_0960
SSA_1030
SSA_1064
SSA_1068
SSA_1103
SSA_1171
SSA_1219
SSA_1271
SSA_1301
SSA_1309

SSA_1363

COG Function
Predicted small periplasmic lipoprotein YifL (function
Unknown
Surface antigen
DNA-binding transcriptional regulator, AcrR family
Ribosomal protein L29
DNA-binding transcriptional regulator, AcrR family
Predicted Fe2+/Mn2+ transporter, VIT1/CCC1 family
Uncharacterized membrane protein YgaE, UPF0421/DUF939
Family
Signal peptidase I
Na+/alanine symporter
Na+/serine symporter
DNA-binding transcriptional regulator, GntR family
DNA-binding transcriptional regulator, MarR family
Glucan-binding domain (YG repeat)
Uncharacterized protein YpbQ, isoprenylcysteine carboxyl
Methy
N/A
Diacylglycerol kinase family enzyme
Uncharacterized surface anchored protein
Predicted transcriptional regulator
Septation ring formation regulator EzrA
Signal transduction histidine kinase
DNA-binding transcriptional regulator, AcrR family
N/A
DNA-binding transcriptional regulator, LysR family
N/A
Integrase
Sortase (surface protein transpeptidase)
nanoRNase/pAp phosphatase, hydrolyzes c-di-AMP and
oligoRNAs
N/A
Predicted RNA-binding protein YlqC, contains KH domain,
UPF010

CubicO group peptidase, beta-lactamase class C family
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Operon/Synteny

Paralogues

SSA_0004
SSA_0036
SSA_0048-0047
SSA_0143-0104
SSA_0144-0145
SSA_0311-0297
SSA_0311-0297
SSA_0350-0352
SSA_0363-0359
SSA_0364
SSA_0387-0385
SSA_0505-0456
SSA_0613-0610
SSA_0706-0708
SSA_0767-0746
SSA_0767-0746
SSA_0802-0812
SSA_0815-0820
SSA_0873-0783
SSA_0923-0963
SSA_1030
SSA_1064
SSA_1065-1122
SSA_1065-1122
SSA_1171
SSA_1218-1220
SSA_1271-1272
SSA_1301-1318
SSA_1301-1318

SSA_1363-1366

1363 vs 1368=
20% coverage, E53,ID 77%; 1363
vs 1371= 100%
cov, E 0, ID 58%

SSA_1368

CubicO group peptidase, beta-lactamase class C family

SSA_1368-1372

SSA_1371

CubicO group peptidase, beta-lactamase class C family
ATP-dependent exoDNAse (exonuclease V) beta subunit
(contains
Phosphoglycerol transferase MdoB or a related enzyme of
AlkP s
ABC-type cobalamin/Fe3+-siderophores transport system,
ATPase
ABC-type Fe3+-siderophore transport system, permease
Component
Membrane protein insertase Oxa1/YidC/SpoIIIJ, required for
The
Serine/threonine protein kinase
N/A
N/A
MFS family permease
Predicted RNA-binding protein Jag, conains KH and R3H
Domains
Uncharacterized membrane protein YeaQ/YmgE,
transglycosylase-a
Membrane associated serine protease, rhomboid family
Transcription antitermination factor NusG
Phosphatidylserine/phosphatidylglycerophosphate/cardiolipin
Sy
N/A
Poly D-alanine transfer protein DltD, involved inesterificatio
D-alanyl-lipoteichoic acid acyltransferase DltB, MBOAT
Superfamily
N/A
3-oxoacyl-[acyl-carrier-protein] synthase III
N/A
Uncharacterized membrane protein

SSA_1368-1372

SSA_1451
SSA_1476
SSA_1741
SSA_1744
SSA_1792
SSA_1845
SSA_1984
SSA_2094
SSA_2128
SSA_2138
SSA_2150
SSA_2170
SSA_2205
SSA_2234
SSA_2320
SSA_2331
SSA_2333
SSA_2335
SSA_2346
SSA_2364
SSA_2386
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1368 vs 1363:
cov= 99%, e 52,
77% ID
1371 vs
1363=100% cov, E
0, ID 58%

SSA_1402-1475
SSA_1476-1479
SSA_1741-1744
SSA_1744-1741
SSA_1792-1791
SSA_1840-1852
SSA_1972-2019
SSA_2082-2121
SSA_2122-2129
SSA_2136-2150
SSA_2150-2136
SSA_2170-2185
SSA_2205
SSA_2211-2246
SSA_2321-2296
SSA_2330-2335
SSA_2330-2335
SSA_2330-2335
SSA_2346-2360
SSA_2364-2371
SSA_2150-2136

Not a paralog
Not a paralog
Not a paralog

Table 4. Potential targets for SPase I.
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Table 4.
Gene

Description

Molecular Weight
(Da)

Paralogue

SSA_0012

Beta-lactamase class A, putative

48396.6418

No

SSA_0015

Membrane ATPase FtsH, degrades sigma32 (integral
membrane cell-division Zn metallo-peptidase), putative

72536.7981

No

SSA_0017

Cell shape determining protein MreC, putative

29544.234

No

SSA_0019

Secreted antigen GbpB/SagA; peptidoglycan hydrolase;
PcsB protein precursor, putative

42469.4498

Yes

SSA_0021

Hypothetical protein

19560.3138

No

SSA_0036

Secreted protein, possible function in cell-wall metabolism
(amidase), putative

72153.7086

Yes

SSA_0094

Cell wall metabolism, LysM type protein, putative

38190.3647

Yes

SSA_0140

Copper-translocating P-type ATPase, putative

79654.5004

Yes

SSA_0146
SSA_0157

DNA repair ATPase, putative
Hypothetical protein

84740.3229
9830.5367

Yes
No

SSA_0165

Conserved hypothetical protein

22562.2951

No

SSA_0167

Hypothetical protein (Asparagine/proline-rich)

33290.0671

No

SSA_0173

23S rRNA m1G745 methyltransferase, putative

32071.4906

No

SSA_0175

Penicillin-binding protein 1B, putative

80849.4257

Yes

SSA_0181

Glycosyltransferase (vectorial glycosyl polymerization
(VGP) family), putative

49942.7224

No

SSA_0186

Competence protein ComYC, putative

11434.1479

No

SSA_0187

Competence protein ComYD, putative

15922.1403

No

SSA_0210

Conserved hypothetical protein

10675.0381

No

SSA_0215

Periplasmic sugar-binding protein (ribose porter), putative

36734.0881

Yes

SSA_0218

Sugar-binding periplasmic protein, putative

48332.3799

Yes
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SSA_0227

Collagen-binding surface protein, putative

66956.5729

Yes

SSA_0243

Cyclo-nucleotide phosphodiesterase, putative

86679.2483

Yes

SSA_0257

N-acetylmuramidase/lysin, putative

104901.3981

Yes

SSA_0273
SSA_0291

Hypothetical protein
Oxidoreductase, putative

50478.7114
29913.2519

No
Yes

SSA_0301

Conserved hypothetical protein

21121.8259

Yes

SSA_0303

Surface protein C

162864.2939

Yes

SSA_0304

Bacterial cell wall degradation (CHAP/LysM domains),
putative

23670.7359

Yes

SSA_0396

Conserved hypothetical protein

35467.6105

No

SSA_0398

Conserved hypothetical protein, beta-lactamase family

67219.477

Yes

SSA_0400

Conserved hypothetical protein, beta-lactamase family

67173.1453

Yes

SSA_0424

Exopolysaccharide biosynthesis protein, putative

32497.4588

No

SSA_0453

Type II secretory pathway, pullulanase PulA glycosidase,
putative

136563.4945

Yes

SSA_0477

Cobalamin biosynthesis protein CbiM (ABC-type cobalt
transporter), putative

27984.33

No

SSA_0478

Cobalt transport protein cbiN, putative

11108.6369

No

SSA_0498

ABC-type dipeptide/oligopeptide/nickel transport systems,
permease components, putative

29272.4342

Yes

SSA_0500

Peptide ABC transporter, permease protein, putative

35018.2904

Yes

SSA_0521

Ethanolamine utilization protein EutL, putative

22395.7496

Yes

SSA_0565

Conserved hypothetical protein

92304.059

No

SSA_0607

ABC transporter, permease component, putative

87572.3394

No

SSA_0610
SSA_0613

LemA-like protein, putative
Glucosyltransferase, putative

20939.6228
175399.2

No
Yes
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SSA_0684

Fibril-like structure subunit FibA, putative

139324.4303

Yes

SSA_0689

Penicillin-binding protein 2B, putative

75285.4986

Yes

SSA_0723
SSA_0726

Hypothetical protein
FmtA-like protein, putative

5304.2581
67437.3138

No
Yes

SSA_0747

DD-carboxypeptidase, putative

50393.737

Yes

SSA_0793

DNA-entry nuclease, putative

31237.3587

No

SSA_0801

Mur ligase family protein, putative

49483.2476

No

SSA_0803

Conserved hypothetical protein

27132.1818

No

SSA_0805

Collagen-binding surface protein, putative

60556.5712

Yes

SSA_0871

Cell division protein FtsX, putative

34500.8682

No

SSA_0881

Lipoprotein, putative

25788.1976

Yes

SSA_0897

Two component system histidine kinase, putative

52198.3589

Yes

SSA_0904

CshA-like fibrillar surface protein A

316344.8238

Yes

SSA_0905

CshA-like fibrillar surface protein B

207893.0251

Yes

SSA_0906

CshA-like fibrillar surface protein C

283050.8434

Yes

SSA_0908

ABC-type uncharacterized transport system, periplasmic
component, putative

35242.882

No

Hypothetical protein
Surface protein D
Peptidoglycan N-acetylglucosamine deacetylase A,
putative

22254.0843
153644.0111

Yes
Yes

52559.0496

No

SSA_0967

Conserved hypothetical protein

24999.4402

No

SSA_0970

Conserved hypothetical protein

17131.3139

Yes

SSA_0991

Deoxyribonuclease, putative

28746.0106

No

SSA_1018

Zinc metalloprotease zmpC precursor, putative

339189.1463

Yes

SSA_1019

Collagen-binding surface protein, putative

87795.544

Yes

SSA_1023

Von Willebrand factor-binding protein precursor, putative

100844.6464

No

SSA_0947
SSA_0956
SSA_0963
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SSA_1042

Xylanase/chitin deacetylase, putative

35656.9693

No

SSA_1051

Spermidine/putrescine ABC transporter,
spermidine/putrescine-binding protein, putative

40929.175

No

SSA_1052

Hypothetical protein

14191.2411

No

SSA_1063

Peptidoglycan-binding domain-containing protein, putative

48445.9462

No

SSA_1064

Conserved hypothetical protein (contains glucan-binding
domain)

28533.3142

Yes

SSA_1065

Beta-hexosamidase A, putative

99533.6984

No

SSA_1095

Peptidoglycan hydrolase, putative

25795.2184

No

SSA_1106

IgA-specific metalloendopeptidase

208437.007

Yes

SSA_1112

Cell wall surface anchor family protein, putative

56954.5939

No

SSA_1118

Peptide methionine sulfoxide reductase, putative

41843.5912

Yes

SSA_1130

Iron-dependent peroxidase, putative

45410.802

No

SSA_1132

TatC, sec-independent protein translocase, putative

28740.0497

No

SSA_1148

Beta-glucosides PTS, EIIC, putative

47963.4949

Yes

SSA_1158

Conserved hypothetical protein

31692.5521

Yes

SSA_1161

Conserved hypothetical protein, possibly secreted

35214.2297

No

SSA_1219

Sortase, putative

27918.7002

Yes

SSA_1221

L-lactate dehydrogenase, putative

35328.6664

No

SSA_1234
SSA_1274

5'-nucleotidase, putative
Hypothetical protein

76340.7606
74589.9418

Yes
No

SSA_1301

Conserved uncharacterized protein, possible surface protein

90577.9472

Yes

SSA_1339

Pneumococcal histidine triad protein D precursor, putative

131547.081

Yes

78675.5391

Yes

66457.5498
35566.1972
12234.0033
67107.2338
66339.2022

Yes
Yes
Yes
Yes
Yes

SSA_1359
SSA_1363
SSA_1365
SSA_1368
SSA_1369
SSA_1371

Arginine/histidine ABC transporter, permease component,
putative
FmtA-like protein, putative
FmtA-like protein, putative
Hypothetical protein
FmtA-like protein, putative
FmtA-like protein, putative
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SSA_1372
SSA_1390
SSA_1391

Hypothetical protein
Hypothetical protein
Hypothetical protein

6968.0981
18387.7033
24811.6397

No
No
No

SSA_1408

Conserved hypothetical protein

21550.7326

No

SSA_1415

Oxidoreductase, putative

39914.9737

No

SSA_1434

Conserved uncharacterized Firmicutes protein

5894.894

No

SSA_1481
SSA_1489

FmtA-like protein, putative
Hypothetical protein

67460.5781
39767.8167

Yes
Yes

SSA_1525

Lyzozyme M1 (1,4-beta-N-acetylmuramidase), putative

32425.9415

No

SSA_1532

Membrane-fusion protein / periplasmic component of
efflux system, putative

40852.7964

Yes

SSA_1544

Conserved uncharacterized protein

17995.4248

No

SSA_1567

Polar amino acid ABC transporter, amino acid-binding
protein, putative

29898.7625

Yes

101024.5143

No

75007.1993
61779.1816

Yes
Yes

SSA_1591
SSA_1593

Conserved ABC-type antimicrobial permease-like protein,
putative
Dipeptidase, putative
Dipeptidase, putative

SSA_1594

Metalloendopeptidase, putative

79277.3956

Yes

SSA_1596
SSA_1597
SSA_1598
SSA_1599

Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein

36580.2214
37837.2035
36877.3853
38230.0062

Yes
Yes
Yes
Yes

SSA_1626

DNA translocase ftsK, putative

84255.6297

Yes

SSA_1631
SSA_1632

Sortase-like protein, putative
Surface protein, putative

33177.1937
51822.5553

Yes
Yes

SSA_1633

FimA fimbrial subunit-like protein, putative

51569.2038

Yes

SSA_1634

Heme utilization/adhesion exoprotein, putative

53218.4441

Yes

SSA_1635

Hypothetical protein

77849.1805

Yes

SSA_1649

Conserved hypothetical transmembrane protein

37430.4913

Yes

SSA_1650

3-Ketoacyl-ACP reductase, putative

25126.5123

Yes

SSA_1653

Hypothetical protein

37671.6974

Yes

SSA_1588
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SSA_1663

Collagen-binding protein A

163017.8908

Yes

SSA_1671

Conserved hypothetical protein

35911.9174

No

SSA_1673

Hypothetical protein

6245.3806

No

SSA_1680

ABC-type bacitracin resistance protein A, permease
component, putative

74398.8545

Yes

SSA_1692

Phospho-B-galactosidase LacG, putative

54094.9495

Yes

36333.7876

Yes

80467.6835

No

SSA_1750

Iron compound ABC transporter, permease protein,
putative
Extracellular nuclease, putative

SSA_1793

Histidine kinase (sensor protein), putative

47218.5222

Yes

SSA_1871

Penicillin-binding protein 2X, putative

84338.3141

Yes

SSA_1882

Subtilisin-like serine proteases, putative

162877.6003

Yes

SSA_1909

Transcriptional attenuator LytR, putative

44849.8077

Yes

SSA_1951

Penicillin-binding protein 3, putative

45867.2977

Yes

SSA_1960

Conserved hypothetical protein

70290.9424

No

SSA_1961

Amino acid ABC transporter, amino acid-binding
protein/permease protein, putative

57437.3438

Yes

SSA_1984

Cell surface SD repeat antigen precursor, putative

99884.0631

Yes

SSA_1985

Conserved hypothetical protein

72476.2762

Yes

SSA_1991

Pneumococcal histidine triad protein A, putative

90478.1281

Yes

SSA_2004

Zinc metalloprotease zmpB precursor, putative

209552.9886

Yes

SSA_2014

D-alanyl-D-alanine carboxypeptidase, putative

28870.2489

Yes

SSA_2020

Conserved hypothetical protein

114163.2144

No

SSA_2023

Fructan beta-fructosidase precursor, putative

155910.6148

Yes

SSA_2056

Cinnamoyl ester hydrolase, putative

34354.6188

Yes

SSA_2060

Arabinose efflux permease, putative

42316.0242

No

SSA_2074

Preprotein translocase subunit YajC, putative

12123.8761

No

SSA_1744

41

SSA_2101

Amino acid ABC transporter, periplasmic amino acidbinding protein, putative

32773.4118

Yes

SSA_2103

Hypothetical protein

7403.5321

No

SSA_2121

Cell wall surface anchor family protein, putative

171211.2214

Yes

SSA_2169

Glucose-1-phosphate uridylyltransferase, putative

35605.5304

Yes

SSA_2248

Conserved hypothetical protein

18481.9426

No

SSA_2250

ABC-type antimicrobial peptide transporter, permease
component, putative

74446.4569

No

SSA_2264

Conserved hypothetical protein

18976.0874

No

SSA_2269

Conserved hypothetical protein

34777.2793

Yes

SSA_2281

Conserved hypothetical protein

17118.3266

No

SSA_2282

Phage infection protein, putative

107220.5308

Yes

SSA_2301

S-layer protein/ peptidoglycan endo-beta-Nacetylglucosaminidase, putative

21506.3392

No

SSA_2307
SSA_2313
SSA_2320

Hypothetical protein
Hypothetical protein
Hypothetical protein

56585.6564
16101.3788
125568.1653

No
Yes
No

SSA_2321

Cation (Co/Zn/Cd) efflux protein, putative

32405.2702

Yes

SSA_2338

Conserved uncharacterized protein

35945.4865

Yes

SSA_2340

Conserved hypothetical protein

43813.4783

No

19901.7084

No

40827.0835

No

SSA_2364
SSA_2381

Immunodominant staphylococcal antigen A precursor,
putative
DegP protein, putative
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Table 5. Potential targets for SPase I that affect biofilm formation
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Table 5.
Gene ID
XG2_0036
XG2_0613
XG2_0805
XG2_1064
XG2_1219
XG2_1301
XG2_1363
XG2_1368
XG2_1371
XG2_1744
XG2_1984
XG2_2320
XG2_2364

Gene Annotation
Secreted protein, possible function in cell-wall metabolism
(amidase), putative (N-acetylmuramoyl-L-alanine amidase)
Glucosyltransferase, putative
Collagen-binding surface protein, putative
Hypothetical protein (dextransucrase/glucansucrase, Nacetylmuramoyl-L-alanine amidase, family 2 )
Sortase, putative
Conserved uncharacterized protein, possible surface protein
FmtA-like protein, putative
Hypothetical protein (beta-lactamase)
FmtA-like protein, putative (beta-lactamase family protein)
Iron compound ABC transporter, permease protein, putative
Cell surface SD repeat antigen precursor, putative
Uncharacterized protein
Immunodominant staphylococcal antigen A precursor, putative
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Figure 2. Crystal violet assay of 51 biofilm mutants. Yellow star signifies selected mutant,
XG2_0351. Panel 1 of each plate contains the blank. Panel 2 of each plate contains SK36.
Panels 3-12 of each plate contain the mutants.
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Figure 3. Biofilm imaging by confocal laser scanning microscopy (CLSM) of 24 mutants that
have shown to affect biofilm formation through preliminary data. Each WT and mutant was
repeated 3 times each (A-C).
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Figure 4. Biofilm imaging by confocal laser scanning microscopy (CLSM) of mutant selected
for further study, XG2_0351. This mutant is one of two type I signal peptidases in S. sanguinis.
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Figure 5. Comparison of (A) SK36 and (B) XG2_0351 morphologies using scanning electron
microscopy at 600 nm with 15 min intervals.
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Figure 6. Three trials comparing the growth of SK36 with XG2_0351 using the plate reader.
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Figure 7. (A) STRING analysis of protein-protein interactions of XG2_0351 and (B) gene co-

occurrence network.
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Figure 8. Biofilm imaging using confocal laser scanning microscopy (CLSM) of downstream
mutant, XG2_0350.
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Figure 9. Biofilm imaging using confocal laser scanning microscopy (CLSM) of SPase I
paralog, XG2_0849.
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Figure 10. Quantitative data for confocal images. Relative intensity of biofilm formation
was measured for SK36, XG2_0351, XG2_0350, and XG2_0849.
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Figure 11. Whole protein extraction from bacterial strains SK36 and mutant sample were
separated by SDS-PAGE and stained with coomassie blue. The arrows indicate possible
proteins that have been shown to reduce biofilm formation by confocal imaging.
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DISCUSSION
Oral biofilm formation in streptococci has shown to be involved in a variety of microbial infections in
the human body, through recruiting diverse bacterial species to site of infection and displaying an effective
defense system against host immune defenses (Hall, McGillicuddy et al. 2014). Biofilm formation involves
numerous stages, namely attachment, maturation, and dispersion (Lister, Horswill 2014, Foster, Geoghegan et
al. 2014). Streptococcus sanguinis has been shown to be involved in biofilm formation (Xu, Alves et al. 2007,
Kolenbrander, London 1993). Investigating the S. sanguinis genes involved in biofilm formation will be
indispensable in uncovering potential drug targets against diverse bacterial infections that involve biofilm
formation in the oral cavity.
A set of 51 non-essential genes (Table 2) was screened previously in our lab for the ability to affect
biofilm formation using microtiter assay as described by O’Toole (O'Toole 2011). This constituted the starting
point for the project of studying S. sanguinis genes involved in biofilm formation. Bioinformatically, we
identified for every biofilm related gene functions using clusters of orthologous groups (COGs) annotations
(Table 3), as described by Uniprot, as well as operon (and genetic neighbors) and the presence/absence of
paralogues (using BLAST with identity >70% and E-value cutoff 10-7 ) (Table 3). On the wet lab level, we ran
a microtiter assay with crystal violet (CV) staining to confirm the previous findings, which concurred to a high
degree to the previous findings. Out of 51 mutants, 25 mutants that exhibited a reduced biofilm formation as
shown by CV staining (Figure 2) were further investigated using confocal laser scanning microscopy (CLSM).
The CLSM images, obtained in triplicates from every mutant, showed variant patterns in biofilm reduction
(Figure 3).
Mutant XG2_0351 was selected for further study in this project based upon results that were obtained
through crystal violet staining and CLSM images (Figure 4). The biofilm formation of XG2_0351 showed
significant reduction in biofilm formation, as compared to SK36 through CV staining, which was later
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conclusively ascertained through CLSM. Contrasting greatly with the biofilm formed by SK36, there was
essentially no biofilm formation observed in either experiment when the XG2_0351 gene was knocked out.
Downstream mutant, XG2_0350, was visualized using CLSM to eliminate the possibility of the polar effect
(Figure 8). Consequently, XG2_0351, one of two signal peptidase I (SPase I) enzymes in S. sanguinis, was
selected for investigation in this project because of considerable phenotypic differences from SK36, in terms of
biofilm formation, and also because little information is known about the role that type I signal peptidase plays
in biofilm formation in this bacterium. Furthermore, even less is known about how SPase I affects biofilm in a
bacterium with multiple SPase I enzymes.
To further investigate the phenotypic role of XG2_0351 gene on biofilm formation, we used SEM to
visualize the morphological differences in growth between the SK36 and SPase I mutant, XG2_0351. The
images (Figure 5) show that the XG2_0351 chains are shorter in length and remain stunted in growth in
comparison to the long chains formed by the wild type. In bacteria, the cell wall bears the stress and helps
maintain the shape, and is important for cell viability. The scaffold of the cell wall consists of the cross-linker
polymer peptidoglycan. Studies have demonstrated that there is a relationship between peptidoglycan synthesis,
bacterial growth, and cell shape (Scheffers, Pinho 2005). Mutants that lack one or several enzymes involved in
the synthesis of peptidoglycan or other cell wall components display changes in cell shape. Molecular analyses
of another member of viridans, S. gordonii, showed that some genes required for biofilm formation are involved
in peptidoglycan biosynthesis (Loo, Corliss et al. 2000). Therefore, we can conclude that in SK36 the SPase I is
necessary to cleave proteins which are crucial to maintain cell shape and cell wall, possibly through
peptidoglycan synthesis.
To gain additional information about the growth disparities between SK36 and XG2_0351, comparison
of growth curves between wild type and XG2_0351 using a plate reader (Figure 6). The exponential
(logarithmic) portions of the resulting growth curves are useful for determining growth rates. Although the SEM
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pictures depict phenotypic differences in morphology between SK36 and mutant, the growth curves show no
substantial difference in rate of growth. The OD values remain comparable for both which means that this
SPase I has demonstrated no substantial role in cell growth. In many bacteria that have been analyzed so far,
type I signal peptidase has been proven to be essential for cell viability (Sharma, Pradhan et al. 2005, Paetzel,
Karla et al. 2002, Date 1983, Klug, Jager et al. 1997). For example, E. coli strain IT41 possesses a mutated
leader peptidase gene, which has a drastically reduced growth rate. The growth rate was reduced because E. coli
only has one SPase I (Sharma, Pradhan et al. 2005, Inada, Court et al. 1989). In contrast to these findings, S.
sanguinis does not show a diminished growth rate when this SPase I is knocked out.
Defining the link between XG2_0351 and biofilm formation on a molecular level demands
characterizing the mechanism of action in details, including substrates of XG2_0351. This is a challenging task
given the fact that S. sanguinis possesses two type I signal peptidases, namely XG2_0351 and XG2_0849,
which may share the same pool of substrates. This led to further examination of bacteria that have multiple
SPases I, a common feature of gram-positive bacteria (Bonnemain, Raynaud et al. 2004). In E. coli the SPase I
is essential for cell viability but S. sanguinis has proven to sustain life even without this enzyme as seen in
knockout experiments and growth curves (Figure 6). XG2_0351 is not essential because the other SPase I in S.
sanguinis, XG2_0849, functionally compensates with respect to cell viability when XG2_0351 is absent. Some
other types of bacteria that share this characteristic with S. sanguinis are Streptomyces, S. lividans, L.
monocytogenes, and B. japonicum (Bonnemain, Raynaud et al. 2004).
The largest number of type I signal peptidases in one single species thus far have been found in grampositive eubacterium Bacillus subtilis. Five genes that specify type I signal peptidases present on the B. subtilis
chromosome. Studies have shown that these enzymes, denoted as SipS, SipT, SipU, SipV, and SipW, have
different but overlapping substrate specificities (Sharma, Pradhan et al. 2005). There are two main advantages
of having multiple SPase I encoding genes in B. subtilis. First there is a broader substrate specificity or
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preference and secondly, a modulation of activity in response to high demands on the secretion machinery
(Bron, Bolhuis et al. 1998, Bolhuis, Sorokin et al. 1996). Unlike the SPase I in E. coli, SipS was not essential
for viability of the cell nor for protein secretion. Although in the absence of SipS, the rate of processing of
several preproteins was reduced (Bolhuis, Sorokin et al. 1996). These sip genes are not essential individually
but a specific combination of mutations in these genes is lethal (Bron, Bolhuis et al. 1998). It will be intriguing
to discover if the same scenario will occur in S. sanguinis once both SPase I genes are knocked out.
To gain further clues regarding the molecular mechanism of action of XG2_0351, we searched
XG2_0351 in the STRING database for protein-protein interaction networks from known metabolic pathways,
protein complexes, signal transduction pathways, and other carefully selected databases (Figure 7A). The
information obtained is from experimental data, computational prediction methods, and public text collections.
Knowledge of protein-protein interactions is essential to understand cellular processes at the system-level. The
protein-protein interaction network of XG2_0351 visualized by STRING revealed that this SPase I protein
interacts with several ribosomal proteins. Ribosomal subunits that are involved in the cellular process of
translation are composed of these proteins and rRNA. This SPase I also interacts with SRPR and SRP54
proteins which are signal recognition particles involved in targeting and inserting nascent membrane proteins
into the cytoplasm. One or more SRP protein in conjunction with SRP RNA contributes to the binding and
release of signal peptide. Then the SPase I proteolytically cleaves them from translocated precursor proteins
from the extracytoplasmic site of the membrane (Auclair, Bhanu et al. 2012, du Plessis, Nouwen et al. 2011).
Gene co-occurrence visually displayed the gene families whose occurrence patterns across genomes
show similarities (Figure 7B). For each gene of interest, the color indicates the similarity of its best hit in a
given STRING genome. The similarities in these presence/absence profiles can predict interactions. Two
distinct colors indicate the lowest and highest similarity observed within that clade. The highest similarities are
in Firmicutes, which mostly have gram-positive cell wall structure. Listeria monocytogenes, a member of
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Firmicutes, has three contiguous SPase I genes called SipX, SipY and SipZ. The major SPase I of L.
monocytogenes is SipZ because the amounts of extracellular virulence factors such as listeriolysin O,
phosphatidylcholine C, and zinc metalloproteinase were significantly decreased upon inactivation. For the
majority of Sec-secreted exoproteins identified, the three SPases I were found to function redundantly. This
became clear when protein secretion was not affected by the inactivation of only one or two of the SPases I.
Since the SipZ of L. monocytogenes applies only to a small subset of the secreted exoproteins, the concept of
minor and major SPases appears to be relative, not absolute (Bonnemain, Raynaud et al. 2004, Renier, Chafsey
et al. 2015). In order to compare the type I signal peptidases in S. sanguinis, CLSM images of XG2_0351
paralogue, XG2_0849, were compared to images of SK36.
In order to investigate the potential role of the other SPase I, XG2_0849, in biofilm formation, we
compared the biofilm formation between S. sanguinis wild type and XG2_0849 using confocal microscopy
(Figure 9). The CLSM image of XG2_0849 showed a slight difference when assessed against SK36 but not as
drastically as XG2_0351. There is a possibility that XG2_0351 is responsible for cleaving more biofilm related
proteins than XG2_0849. The quantitative data obtained by measuring the relative intensities of confocal
images (Figure 10) clearly illustrated that XG2_0351 biofilm is ten-fold decreased when compared to SK36,
whereas the downstream mutant (XG2_0350) and parlogue (XG2_0849) were not significantly different from
the wild type. In S. sanguinis, XG2_0351 appears to be the major SPase I when biofilm formation is concerned.
This scenario was shown to occur in P. aeruginosa, which has two noncontiguous SPases I. PA1302 is involved
with quorum-sensing cascade and includes the suppression of virulence factor secretion and virulenceassociated phenotypes, while LepB is the primary SPase (Waite, Rose et al. 2012).
Finally, to narrow the list of potential substrates of XG2_0351 involved in biofilm formation, we
extracted whole cell proteins from S. sanguinis wild type and compared it to that from XG2_0351 (Figure 11).
The amount of protein extracted from wild type was almost two-fold the amount extracted from XG2_0351. We
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further separated the extracted proteins by SDS-PAGE and stained with Coomassie-Brilliant Blue. Nine
substrates of SPase I enzyme, XG2_0351, which were previously shown through CV staining (Figure 2) and
confocal imaging (Figure 3) to exhibit reduced biofilm formation, were absent in XG2_0351 mutant in
comparison to wild type. These may provide clues about molecular mechanism adopted by XG2_0351 to affect
biofilm formation and provide a potential drug target with promising impact on reducing biofilm formation.
Further study is necessary to claim that XG2_0351 is to S. sanguinis what SipZ is to L. monocytogenes.
The predominance of one SPase I over another is a bacterium is dependent on more than biofilm formation
factors. The major SPase I is essential for efficient protein secretion which is contingent upon the availability of
SPases, the production levels of secreted proteins, and substrate specificity or substrate preference of the
different type I SPases (Bolhuis, Sorokin et al. 1996). Coomassie blue staining was done to measure the levels
of proteins in SK36 and XG2_0351.
This study indicates that type I signal peptidase mutant, XG2_0351, causes a decrease in biofilm
formation when compared to SK36. This SPase I performs a more critical role in biofilm formation than
XG2_0849. Gene 0351 is possibly necessary for functions that include but are not limited to cell-wall
metabolism, collagen-binding, iron transportation, and antibiotic resistance (Table 5 & Figure 11). These
contribute to the successful formation of biofilm in S. sanguinis. Future studies may further the investigation by
creating a double knockout mutant of both XG2_0351 and XG2_0849 and measuring cell viability. Pulse-chase
protein radiolabeling would give a deeper understanding of the activity of proteins over a prolonged period of
time. Mass spectrometry could be utilized to reveal which proteins are missing in XG2_0351 and therefore,
which proteins are affecting biofilm formation in S. sanguinis.
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